268 related articles for article (PubMed ID: 16362411)
1. Tumor escape mechanisms in prostate cancer.
Miller AM; Pisa P
Cancer Immunol Immunother; 2007 Jan; 56(1):81-7. PubMed ID: 16362411
[TBL] [Abstract][Full Text] [Related]
2. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
[TBL] [Abstract][Full Text] [Related]
3. Immunology and immunotherapy approaches for prostate cancer.
Elkord E
Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive strategies that are mediated by tumor cells.
Rabinovich GA; Gabrilovich D; Sotomayor EM
Annu Rev Immunol; 2007; 25():267-96. PubMed ID: 17134371
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for prostate cancer.
Rini BI; Small EJ
Curr Oncol Rep; 2001 Sep; 3(5):418-23. PubMed ID: 11489243
[TBL] [Abstract][Full Text] [Related]
6. Dendritic-cell vaccination for prostate cancer.
Thomas-Kaskel AK; Veelken H
Immunotherapy; 2009 Jan; 1(1):63-72. PubMed ID: 20635974
[TBL] [Abstract][Full Text] [Related]
7. Cutibacterium acnes Induces the Expression of Immunosuppressive Genes in Macrophages and is Associated with an Increase of Regulatory T-Cells in Prostate Cancer.
Davidsson S; Carlsson J; Greenberg L; Wijkander J; Söderquist B; Erlandsson A
Microbiol Spectr; 2021 Dec; 9(3):e0149721. PubMed ID: 34937192
[TBL] [Abstract][Full Text] [Related]
8. Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer.
Sutherland SIM; Ju X; Horvath LG; Clark GJ
Front Immunol; 2021; 12():641307. PubMed ID: 33854509
[TBL] [Abstract][Full Text] [Related]
9. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
Shafer-Weaver KA; Watkins SK; Anderson MJ; Draper LJ; Malyguine A; Alvord WG; Greenberg NM; Hurwitz AA
Cancer Res; 2009 Aug; 69(15):6256-64. PubMed ID: 19622771
[TBL] [Abstract][Full Text] [Related]
10. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.
Sanchez C; Chan R; Bajgain P; Rambally S; Palapattu G; Mims M; Rooney CM; Leen AM; Brenner MK; Vera JF
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):123-31, S1. PubMed ID: 23295316
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
12. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
[TBL] [Abstract][Full Text] [Related]
13. Signaling defects in anti-tumor T cells.
Frey AB; Monu N
Immunol Rev; 2008 Apr; 222():192-205. PubMed ID: 18364003
[TBL] [Abstract][Full Text] [Related]
14. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
Rolinski J; Hus I
J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
[TBL] [Abstract][Full Text] [Related]
15. Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy.
Vavrova K; Vrabcova P; Filipp D; Bartunkova J; Horvath R
Med Oncol; 2016 Dec; 33(12):136. PubMed ID: 27812850
[TBL] [Abstract][Full Text] [Related]
16. Development of novel immune interventions for prostate cancer.
Agarwal N; Padmanabh S; Vogelzang NJ
Clin Genitourin Cancer; 2012 Jun; 10(2):84-92. PubMed ID: 22409862
[TBL] [Abstract][Full Text] [Related]
17. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the properties of dendritic cells in the pursuit of immunological tolerance.
Horton C; Shanmugarajah K; Fairchild PJ
Biomed J; 2017 Apr; 40(2):80-93. PubMed ID: 28521905
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer vaccines: current status and future potential.
Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
[TBL] [Abstract][Full Text] [Related]
20. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
